Zacks.com on MSN3h
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for UrticariaThe FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...
Veteran broadcaster Alan Jones has been charged with historical indecent assault and sexual touching offences spanning two decades.
Language barriers and inexperience may hamper North Korean troops on Russia’s battlefield © 2024 NBCUniversal Media, LLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback